ISRCTN10768387进行中（未招募）未知
Clinical demonstration for three-level prevention intervention of birth defect on monogenic disease (deafness)
Chinese PLA General Hospital0 个研究点目标入组 10,000 人开始时间: 2020年6月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Congenital hearing loss or late-onset hearing loss and their families
- •2. Patients with congenital malformation of auditory organ and their families
- •3. Acquired sensorineural hearing loss patients and their families
- •4. Hearing normal individuals with a family history of deafness
排除标准
- •1. The patients and their families who refused to participate in the program after receiving the education by doctors
- •2. The patients with deafness caused by non-genetic factors were definitely diagnosed
研究者
相似试验
已完成
不适用
Research on Three-level Prevention and Intervention for Elderly Depression in Urban CommunityDepression in Old AgeNCT06132061Affiliated Hospital of Yunnan University327
进行中（未招募）
不适用
A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - N/Ahigh-risk diffuse large B-cell lymphoma (DLBCL )EUCTR2005-004630-41-DEEli Lilly and Company limited709
进行中（未招募）
不适用
A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - PRELUDEHigh-risk diffuse large B-cell lymphoma (DLBCL)EUCTR2005-004630-41-GREli Lilly and Company Limited459
进行中（未招募）
不适用
A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - Preludehigh-risk diffuse large B-cell lymphoma (DLBCL )EUCTR2005-004630-41-DKEli Lilly and Company limited709
进行中（未招募）
1 期
A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - N/Ahigh-risk diffuse large B-cell lymphoma (DLBCL )MedDRA version: 14.1Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851EUCTR2005-004630-41-CZEli Lilly and Company Limited709